Daiichi Sankyo Europe GmbH’s Post

EVENT | Mingle and discuss Drug Discovery: from preclinical to clinical phase with us on September 21st! Looking forward to meeting you! #Recipharm #UBP #DrugDiscovery #preclinical #clinicalphase

🏥 𝗨𝗻𝗺𝗮𝘁𝗰𝗵𝗲𝗱 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗥𝗢 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲: 𝗣𝗮𝗹𝗹𝗲𝗼𝘀 & 𝗢𝗖𝗧 𝗚𝗹𝗼𝗯𝗮𝗹 𝗝𝗼𝗶𝗻 𝗙𝗼𝗿𝗰𝗲𝘀 💊 𝗜𝗻 𝗠𝗮𝘆 𝟮𝟬𝟮𝟰, palleos healthcare and #OCTGlobalSA, which operates as OCT Clinical, recently combined under the Palleos brand. Geographically speaking, the merger comes with several benefits: Palleos, situated in #Germany, mostly serves Western and Central Europe, whereas OCT's region includes Eastern Europe. Together, they now offer a product portfolio spanning from pre-clinical consulting to regulatory affairs and #clinicaltrials, covering the entire #region.Palleos primarily focused on developing products for the #oncologymarket, which included strategizing preclinical and clinical research💉💉, managing trials, and gathering data after the medicine💊 was launched in markets. Operating for studies in oncology, rheumatology, #infectiousdiseases, and other fields, OCT was a full-service CRO. Swiss Xlife Sciences AG, a significant shareholder in Palleos and a life sciences incubator, assisted to negotiate the purchase. 𝑩𝒓𝒐𝒘𝒔𝒆 𝒂𝒕 𝒐𝒖𝒓 𝑳𝒊𝒏𝒌𝒆𝒅 𝑹𝒆𝒑𝒐𝒓𝒕 👉: https://bit.ly/3V6FaAN #PalleosHealthcare #OCTGlobalSA #ContractResearchOrganisation #CRO #MergersAquisitions #prophecymarketinsights

International Drug Repurposing Conference – #iDR24    REMEDi4ALL is an EU-funded project that aims to build a sustainable European innovation platform to enhance the repurposing of medicines for all.  As part of the project's aim to reach this initiative, consortium members are co-organising, with Beacon for Rare Diseases and MeRIT, the International Drug Repurposing Conference 2024 (#iDR24): Bridging Boundaries for Innovative Drug Repurposing. The conference will unite key players in drug repurposing and showcase how patient communities, researchers, industry, and health authorities can benefit from cutting-edge drug repurposing.     As a member of the consortium, Syreon Research Institute will be represented at the conference by Dalma Hosszú and Zsuzsanna Petykó, who will chair a panel session titled "Getting repurposed drugs to patients, focusing on the routes to market, the existing barriers, and the new initiatives designed to improve the landscape." Find out more about the speakers, location, ticket prices and more here: https://lnkd.in/dXTwTK7D     #iDR24 #DrugRepurposingConference #InnovationInMedicine #REMEDi4ALL #Beacon #MeRIT  

Outi Vaarala, Orion`s Senior Vice President, Research and Development, appeared on MTV News current affairs program Huomenta Suomi to discuss investments in the pharmaceutical industry and the important collaboration among industry players. Orion is involved in the entire medicine development process in Finland. The societally significant investments in research and development, high-level expertise in Orion's core therapy areas of cancer and pain, and patients' supportive attitudes towards clinical trials facilitate early-stage medical research. Through investments in research, we aim to create positive impacts on patients' lives both in Finland and globally. 🧪 "Breakthroughs occur in an environment where the ecosystem supports medicine development. Development requires contributions from multiple societal stakeholders." — Outi Vaarala Thank you Anne-Mari Virolainen Managing Director of Lääketeollisuus ry / Pharma Industry Finland, for the great discussion! The program can be viewed in Finnish on MTV Katsomo. #PharmaceuticalIndustry #ResearchAndDevelopment #PharmaceuticalResearch #Orion

This strategic realignment of the development team underscores the company's commitment to maximizing its portfolio value and driving future growth in its core therapeutic areas. Read more 👉 https://lttr.ai/ARRl3 #GlobalDevelopmentTeam #StrategicallyRealigning #KeyTherapeuticAreas #OptimizeResourceAllocation #DrivingFutureGrowth

🌟 Gubra: Coming to America! 🚀 As Gubra, known for their preclinical CRO services and drug discovery programs, expand into the US, they will add to a thriving scene in Boston. They've chosen to start their venture in Boston's Kendall Square. With over half their CRO revenue coming from the US, this strategic move is set to build stronger connections with their American customers. 🤝 Boston's vibrant biotech scene promises collaborative opportunities with leading pharma and biotech players. Gubra's team will be focusing on metabolic, fibrotic, obesity, NASH, lung, and kidney diseases, serving the high-demand US market. 🏥 With CEO, Henrik Blou, at the helm, there are surely great things to come from Gubra's new US office!💡 #CRO #Preclinical #DrugDiscovery #Expansion #Pharma #Biotechnology #ContractResearch

We’re thrilled to announce another milestone for Dalriada Drug Discovery—reaching 10,000 followers on LinkedIn! 🎉✨   🔬 Pioneering Breakthroughs: Our journey has been defined by innovation and a relentless pursuit of scientific excellence. From the inception of Dalriada, our mission has been crystal clear: to be an ultimate partner in drug discovery and bring life-changing therapies to those in need. Each breakthrough, every discovery, and all our efforts are dedicated to this noble cause.   🤝 Community of Changemakers: We owe this achievement to our incredible community—passionate scientists, dedicated researchers, visionary leaders, and supporters who have believed in our mission from day one. Your engagement, feedback, and enthusiasm have been the driving force behind our success. Together, we are not just building a company, but a movement towards a healthier and brighter future.   🌟 Celebrating Progress: As we celebrate this milestone, we also reflect on the significant progress we’ve made. From identifying promising drug candidates to advancing them through rigorous preclinical and clinical trials, every step forward brings us closer to our goal. We're proud of what we've accomplished so far, but we're even more excited about the journey ahead.   🌍 Global Impact: Our reach extends far beyond our laboratory walls. Through collaborations with academic institutions, pharmaceutical partners, and healthcare organizations worldwide, we're amplifying our impact and accelerating the pace of discovery. Together, we're shaping the future of medicine and making a difference in the lives of millions.   🔍 What's Next?: Our journey is far from over. With your continued support, we're poised to achieve even greater milestones. We're doubling down on our commitment to innovation, pushing the boundaries of science, and unlocking new possibilities in drug discovery. Together, we will shape a healthier, happier world for generations to come. Thank you to each and every one of our 10,000 followers for being part of this incredible journey. Your support fuels our passion and drives us forward. Here's to the next chapter of discovery, collaboration, and impact. Together, we're unstoppable.   #DalriadaDrugDiscovery #DrugDiscovery #Innovation #Science #Milestone #Community #Impact #Healthcare #FutureOfMedicine

🔍 Navigating the complexities of pharma deals? Join the 'Pharma Dealmakers Panel: Viewing the Challenges from Both Sides' at #Sachs_ELSF on February 29th, 2024, at the Hilton Zurich Airport Hotel. A deep dive into the intricacies of biopharma collaborations and negotiations. 🌐🤝 Chaired by: Sarah Holland, President of Swiss HLG & CBO, Cureteq AG - a Partex Company Panellists: Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG David Colpman, Director, Alpina Life Science Advisors Emin Fadillioglu, MD, CEO, Eczacıbaşı Topluluğu Pharmaceutical and Industrial Investment Co. Peter L. Braun, CEO, TargImmune Therapeutics AG Ulrich Wendt, Global Head Business Development Immunology & Inflammation, Sanofi Gain unparalleled insights into the challenges and strategies of pharma dealmaking from the perspectives of both biotech innovators and pharma giants. This panel is a must-attend for those looking to understand the dynamics of successful partnerships and investments in the rapidly evolving life sciences landscape. Don’t miss out on this opportunity to network with industry leaders and strategize for success. Register today at www.sachsforum.com/17elsf and be part of the conversation #inperson & #online during the Sachs Spring Life Sciences Week. #PharmaDealmakers #Biopharma #LifeSciences #StrategicPartnerships #InvestmentStrategies #BiotechInnovation #PharmaIndustry #SachsForum #Sachs_ELSF #SachsSpringLifeSciencesWeek #SSLSW

🌐 Exciting Developments in Dystonia Treatment! 🌐 Thrilled to share the latest insights from the #Dystonia #Drugs #Market research report! For Any Queries, Contact Us: https://lnkd.in/d5DMEzc9 🔍 Key Takeaways: 1️⃣ Innovative Therapies: Discover groundbreaking advancements in dystonia drugs, exploring novel therapeutic approaches that hold promise for enhanced patient outcomes. 2️⃣ Market Trends: Gain a nuanced understanding of the current market trends shaping the dystonia drugs landscape. From emerging technologies to evolving patient preferences, this report covers it all! 3️⃣ Global Impact: Explore the global impact of dystonia drugs, with insights into regional dynamics, market drivers, and potential growth opportunities across different geographies. 4️⃣ Collaborative Initiatives: Learn about collaborative initiatives and partnerships driving research and development in the dystonia space. Together, we're pushing boundaries for a brighter future in healthcare! 🔬 This report is a testament to the collective efforts of the healthcare community, dedicated to improving the lives of those affected by dystonia. Let's continue to foster innovation, collaboration, and knowledge-sharing in our pursuit of better health for all. Key Players are: Merz Pharma GmbH & Co KGaA Reinheim (Germany) Ipsen (France) Allergan (Ireland) US WorldMeds (United States) Valeant Pharmaceuticals (Canada) #DystoniaResearch #HealthcareInnovation #MedicalAdvancements #CollaborationForACure

🌟 𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸 𝗘𝘅𝗽𝗮𝗻𝗱𝘀 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗛𝗼𝗿𝗶𝘇𝗼𝗻 𝘄𝗶𝘁𝗵 𝗕𝗼𝘀𝘁𝗼𝗻 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗙𝗮𝗰𝗶𝗹𝗶𝘁𝘆 𝗚𝗿𝗮𝗻𝗱 𝗢𝗽𝗲𝗻𝗶𝗻𝗴! 💫 𝗜𝗻 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰, 🕬🕬 After significant renovations, the former Dicerna facility—which Novo Nordisk has owned since the Danish 💊Pharmaceutical Company acquired the #biotech for $3.3 billion back in 2021—has finally opened. The reconstructed establishment 💉💅was officially unveiled on Wednesday, February 28. This event cemented the Boston region as Novo's second headquarters, after #copenhagen . Novo's R&D investments have been rapidly increasing in tandem with its expanding revenue 💹 due to its 🚑 obesity and #diabetes portfolio, which is headlined by #wegovy and Ozempic, respectively. This coincides with the opening of the new campus. In the fourth quarter, Novo invested almost $1.5 billion, or about 16% of its sales revenue, in research and development🔬. In 2023, total R&D spending increased by 35%, roughly matching the growth in revenues. 𝗟𝗼𝗼𝗸 𝗮𝘁 𝗼𝘂𝗿 𝗖𝗼𝗿𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3T07QKw #novonordisk  #diabetes #obesity  #R&D   #weightloss #prophecymarketinsights